Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech's existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922). Under the terms of the license agreement closed on January 3, 2024, Legend Biotech will receive a $100 million upfront cash payment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.91 USD | +2.62% |
|
+2.80% | -23.70% |
07-04 | Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results | MT |
07-02 | Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.70% | 8.37B | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.20% | 25.98B | |
-24.33% | 19.27B | |
-18.26% | 15.99B | |
-17.95% | 15.66B | |
-48.32% | 14.5B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Corporation Announces Closing of License Transaction for Certain Car-T Therapies Targeting DLL3 with Novartis Pharma AG